HLB Therapeutics Co.,Ltd. (KOSDAQ: A115450)
Health Care · Biotechnology · KR
₩3,175.00
+28.54% today · +11.9% 1Y
HLB Therapeutics Co.,Ltd. (KOSDAQ: A115450) operates in the Biotechnology industry within the Health Care sector. The company is valued at $208.16M.
Over the last twelve months the share price has gained 11.9%, trading between 1.34K and 4.16K.
Tweenvest scores HLB Therapeutics Co.,Ltd. across four factors: quality 58/100, value 62/100, growth 69/100. Its strongest factor is growth.
A115450 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $208.16M
- Revenue (TTM)
- $41.62M
- P/E
- —
- EPS
- -204.73
- Dividend yield
- —
- Beta (5Y)
- -0.53
- 52-week high
- ₩4,160.00
- 52-week low
- ₩1,342.00
- Avg volume (3M)
- —
- Shares outstanding
- 88.14M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Lyell Immunopharma, Inc.NasdaqGS: LYEL | $213.44M | $8.71 | -5.94% |
| Genome & CompanyKOSDAQ: A314130 | $212.80M | ₩5,470.00 | -0.55% |
| Invivyd, Inc.NasdaqGM: IVVD | $212.58M | $0.74 | +2.61% |
| Guangzhou Innogen Pharmaceutical Group Co., LtdSEHK: 2591 | $209.56M | HK$3.60 | -3.49% |
| TaiGen Biopharmaceuticals Holdings LimitedTPEX: 4157 | $207.71M | NT$9.33 | +7.86% |
| Genomictree Inc.KOSDAQ: A228760 | $206.67M | ₩11,320.00 | -7.21% |
| Shanghai Rightongene Biotechnology Co., Ltd.SHSE: 688217 | $204.58M | CN¥24.83 | -3.20% |
| Anbio BiotechnologyNasdaqGM: NNNN | $204.53M | $4.66 | -16.04% |
Figures last refreshed Oct 11, 2026.